vildagliptin / Generic mfg. - LARVOL DELTA

Vildagliptin-Associated Acquired Hemophilia A. (PubMed, Ann Pharmacother) - No abstract available

Journal • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. (PubMed, Pharmacoepidemiol Drug Saf) - "DPP-4 inhibitors remain effective and well-tolerated options for managing T2DM."

Journal • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review. (PubMed, J Pers Med) - " We systematically searched PubMed, Scopus, and Web of Science for studies published from the earliest available records to 18 August 2025 using the following Boolean search terms: "miRNA AND gliclazide", "miRNA AND glibenclamide", "miRNA AND gliquidone", "miRNA AND glimepiride", "mirRNA AND metformin", "miRNA AND pioglitazone", "miRNA AND rosiglitazone", "miRNA AND sitagliptin", "miRNA AND vildagliptin", "miRNA AND alogliptin", "miRNA and saxagliptin", "miRNA AND linagliptin", "miRNA AND liraglutide", "miRNA and dulaglutide", "miRNA AND semaglutide", "miRNA AND tirzepatide", "miRNA AND lixisenatide", "miRNA AND empagliflozin", "miRNA AND dapagliflozin", miRNA AND insulin glargine", "miRNA AND insulin detemir", "miRNA AND insulin degludec", "miRNA AND..."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Development and Validation of High-Performance Thin Layer Chromatographic Method for the Simultaneous Estimation of Dapagliflozin and Vildagliptin in Fixed-Dose Combination. (PubMed, Turk J Pharm Sci) - "The proposed HPTLC method allows for the simultaneous estimation of DAP and VIL with high accuracy, precision, and sensitivity. Owing to its satisfactory analytical performance, the method is suitable for routine quality control of combined dosage forms containing DAP and VIL."

Journal • Diabetes • Metabolic Disorders

Synthesis and Toxicological Evaluation of N-Nitroso Vildagliptin Amide Impurity in BALB 3T3 Clone Cells. (PubMed, J Appl Toxicol) - "These findings confirm that NNVI presents a toxicological risk at concentrations above regulatory limits. The study underscores the importance of strict impurity control in pharmaceutical formulations and contributes to the wider effort of ensuring drug safety by limiting nitrosamine exposure to acceptable thresholds."

Journal • CAT

Gliptin-Induced Bullous Pemphigoid: Are Statins and Angiotensin Receptor Blockers the Cause? (PubMed, Dermatol Ther (Heidelb)) - "This is one of the first studies to compare demographic, clinical, and laboratory characteristics of patients with gliptin-induced and conventional BP. Our results suggest gliptin-associated BP may present with more severe disease. Hyperlipidemia, ARB, and statin use may be associated with DPP4i-induced BP. Although larger studies are warranted to confirm this association, we believe these findings should be kept in mind while choosing patients to treat with gliptins."

Journal • Bullous Pemphigoid • Cardiovascular • Dermatology • Dermatopathology • Diabetes • Dyslipidemia • Hypertension • Immunology • Metabolic Disorders

Bioanalytical Method Development and Validation for the Estimation of Metformin and Vildagliptin in K3EDTA Human Plasma Using HPLCESI- MS/MS. (PubMed, Drug Metab Bioanal Lett) - "The aforementioned technique is reliable and effective for monitoring bioequivalence investigations in human participants."

Journal

Comparative Effects of Empagliflozin and Vildagliptin on Inflammation and Atrial Function in Patients with Type 2 Diabetes and Coronary Artery Disease: EMPA-VILDA-Response trial. (PubMed, Eur J Pharmacol) - "Empagliflozin not only improves metabolic and inflammatory profiles but also confers early benefits on cardiac structure and function in T2DM patients with CAD. These findings highlight the broader cardiovascular utility of SGLT2 inhibitors beyond glycemic control and support their growing role in cardio-protection within clinical practice."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • LEP • SORT1 • TNFA

Effects of empagliflozin and vildagliptin on cognitive impairment in a rat model induced by high-fat diet and low-dose streptozotocin (ECNP 2025) - "Our findings indicate that empagliflozin and vildagliptin treatments ameliorate cognitive deficits induced by diabetes through mechanisms potentially involving neuroprotection, reduced neuroinflammation, enhanced antioxidant capacity, and improved insulin signaling. Empagliflozin and vildagliptin appear to exert complementary effects, particularly when administered in combination, offering robust protection against neuronal damage. These results suggest that these antidiabetic agents may hold therapeutic potential beyond glucose control, providing beneficial effects in managing cognitive impairments associated with diabetes."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Antidiabetes medications and risk of incident depression in people with diabetes mellitus: a 20-year population-based cohort study (ECNP 2025) - "Associations of first-diagnosed depression with exposure duration to antidiabetes medications were examined by Cox proportional hazards model, with adjustment of a comprehensive array of important confounders including age, sex, calendar-year period, catchment area, pre-existing physical comorbidities, alcohol/substance use disorders, cardiovascular and lipid-lowering medication prescriptions, and presence of other antidiabetes medications.ResultsOur results showed that longer exposure to the vast majority of antidiabetes medications, including metformin (HR 0.23 95% CI 0.21-0.25), gliclazide (0.36 [0.33-0.39]), glimepiride (0.46 [0.35-0.61]), glibenclamide (0.55 [0.47-0.65]), pioglitazone (0.29 [0.19-0.43]), sitagliptin (0.40 [0.30-0.54]), linagliptin (0.44 [0.28-0.69]), vildagliptin (0.33 [0.21-0.54]), janumet (0.25 [0.12-0.50]), and insulin (0.78 [0.69-0.88]) were associated with a decreased risk of incident-depression in patients with diabetes relative to minimal..."

Clinical • CNS Disorders • Depression • Mood Disorders • Psychiatry

Association of statins, gliptins, and antipsychotics with bullous pemphigoid: A case-control study in the Cretan population (EADV 2025) - "Higher proportions of use in the BP group vs. control group were found for atorvastatin (OR = 1.86, 95% CI 1.04-3.32, P = 0.035), linagliptin (OR = 6.63, 95% CI 2.17-20.23, P < 0.001), vildagliptin (OR = 3.20, 95% CI 1.73-5.91, P < 0.001), alogliptin (OR = 5.11, 95% CI 1.19-22.04, P = 0.016), and quetiapine (OR = 4.21, 95% CI 1.5-11.85, P = 0.004)...Metformin intake showed no significant association with BP (OR = 0.48, 95% CI 0.18-1.28, P = 0.143)... Our findings confirm and extend previous studies reporting the association of gliptins and antipsychotics on BP in other European populations. The association found for statins is new, thus more studies are needed to corroborate its validity."

Clinical • Bullous Pemphigoid • CNS Disorders • Dermatology • Dermatopathology • Diabetes • Endocrine Disorders • Immunology • Metabolic Disorders

Introducing a Novel Once-weekly Dipeptidyl Peptidase 4 Inhibitor: Trelagliptin in India. (PubMed, J Assoc Physicians India) - "In a randomized phase 3 clinical trial involving patients with glycated hemoglobin (HbA1c) ≥8%, trelagliptin showed greater HbA1c reduction (-1.25%) as compared to vildagliptin (-1.15%) and a similar safety profile. This article outlines the development and regulatory journey leading to trelagliptin's first approval in India by the Central Drugs Standard Control Organization (CDSCO) in December 2024. Phase 4 real-world evidence studies are currently ongoing in India to assess long-term safety and efficacy."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

High-Performance Liquid Chromatography Method for Simultaneous Determination of the Degradation Products of Metformin Hydrochloride and Vildagliptin. (PubMed, Eur J Pharm Sci) - "The response surface graphs were used to identify optimal experimental conditions, aligning fully with the optimized method. The aim of this paper is to present the method development and prove that it suits the intended purpose."

Journal

Dual therapy with vildagliptin and sacubitril/valsartan alleviates portal hypertension and inhibits soluble epoxide hydrolase in cirrhotic rats. (PubMed, World J Gastroenterol) - "Combined DPP4-I with ARNI therapy ameliorates PH and fibrosis via sEH suppression and EET restoration, offering a promising treatment strategy for cirrhosis-related PH."

Journal • Preclinical • Cardiovascular • Fibrosis • Gastroenterology • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension

Evaluation and comparison of efficacy and safety of mitochondrial modulator (Imeglimin) and DPP-4 inhibitors in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis. (PubMed, J Endocrinol Invest) - "Imeg and DPP-4i demonstrated favorable antidiabetic effects and good safety. Imeg exhibited comparable glycemic control to that of DPP-4i. Overall, Alog was the most suitable option among the included DPP-4i for T2DM patients with hyperlipidemia. Tene demonstrated significant efficacy in glycemic control, and can be a first-line choice among the included DPP-4i."

Clinical • Journal • Retrospective data • Review • Diabetes • Dyslipidemia • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

DPP4 and its inhibition has no impact on disease progression and severity in a bullous pemphigoid like mouse model (ESDR 2025) - "In the second approach, to assess the impact of pharmacological DPP4 inhibition, C57BL/6J mice were fed vildagliptin or sitagliptin (6 mg/mL) ad libitum for six weeks prior to disease induction, with control groups receiving vehicle water (n=8 per group). The data imply that DPP4i-induced BP may rather be related to pre-existing disease states, such as diabetes or predisposing genetic variations. Here, susceptible mice will be treated with DPP4i or vehicle before immunization with Col7, and DPP4-deficient mice backcrossed to mice susceptible to BP-like EBA will be compared to DPP4-sufficient litter mates."

Preclinical • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Taming glycaemic excursions: vildagliptin meets closed-loop tech in type 1 diabetes during intermittent fasting of Ramadan (EASD 2025) - P3 | "Adjunctive vildagliptin treatment mitigated postprandial hyperglycemia compared with pre-meal bolus alone. Vildagliptin significantly increased TIR while reducing glycemic variability without compromising safety."

Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes. (PubMed, Cureus) - "In contrast, dapagliflozin may be more suitable for obese patients with low HDL-C. Thus, adding either drug to metformin not only improves glycemic control (FPG and HbA1c) but also favorably influences lipid profiles, potentially reducing ASCVD risk in this population."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • APOB

Protective role of vildagliptin against bisphenol-A induced liver injury: targeting oxidative stress, apoptosis, and endoplasmic reticulum stress. (PubMed, Arch Physiol Biochem) - "The co-administration of Vildagliptin reversed these hazards. The results of this study established the protective effect of Vildagliptin against BPA induced liver dysfunction."

Journal • Hepatology • Liver Failure • BCL2 • CASP3 • XBP1

Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. (PubMed, Cureus) - "Vildagliptin showed a low incidence of hypoglycemic events in comparison with other DPP-4 inhibitors. Overall, this systematic review found no significant superiority of vildagliptin over other DPP-4 inhibitors such as sitagliptin and alogliptin in the management of type 2 diabetes mellitus, whether used as monotherapy or in combination therapy."

Journal • Review • Diabetes • Gestational Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Early treatment with vildagliptin and linagliptin reduces social fear and prevents the onset of comorbid depression in a mouse model of social anxiety disorder. (PubMed, Neuropharmacology) - "Importantly, both gliptins also prevented the onset of comorbid depressive-like behavior in these mice. These results have important clinical connotations, as they suggest that early treatment with DPP4 inhibitors such as sitagliptin, vildagliptin and linagliptin could serve as promising therapeutic strategy for SAD, not only reducing the main symptoms of social anxiety but also the risk of developing comorbid mood disorders that often exacerbate the severity of symptoms and complicate treatment outcomes."

Journal • Preclinical • CNS Disorders • Depression • Diabetes • Metabolic Disorders • Mood Disorders • Psychiatry • Social Anxiety Disorder • Type 2 Diabetes Mellitus

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome (clinicaltrials.gov) - P2/3 | N=60 | Recruiting | Sponsor: October 6 University | Trial completion date: May 2024 ➔ Feb 2026 | Trial primary completion date: Apr 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Polycystic Ovary Syndrome

Combined experimental and computational investigation of vildagliptin: spectroscopy, electronic structure, MD and Docking to EGFR, VEGFR2, and HER2 anticancer targets. (PubMed, J Comput Aided Mol Des) - "Additionally, molecular docking and molecular dynamics simulations confirmed the formation of stable complexes with EGFR, VEGFR2, and HER2 receptor proteins, suggesting potential anticancer activity. The main purpose of this publication is to fill existing gaps in our understanding of VILD's molecular behavior and offer a robust foundation for rational drug design and improved therapeutic strategies."

Journal • Oncology • EGFR • HER-2 • KDR

A case series of vildagliptin-associated bullous pemphigoid - Rare side effect. (PubMed, Indian J Pharmacol) - "Vildagliptin, among the most commonly used, OHA, belongs to group dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus, has recently been associated with bullous pemphigoid, characterized by fluid-filled blisters and erosions on the skin and mucous membranes. We report the series of three cases of bullous pemphigoid in patients of diabetes, who developed bullous pemphigoid after vildagliptin use."

Adverse events • Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Sadat City University | N=100 ➔ 0 | Active, not recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry